Anthera Pharma (ANTH) Misses Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Anthera Pharmaceuticals Provides Business Update and Reports 2016 Second Quarter Financial Results
August 9, 2016 8:35 AM EDTMet enrollment target in SOLUTION study and enrolled first patient in SIMPLICITY study of SollpuraSuccessful sachet manufacturing to support SIMPLICITY study and commercial-scale lipase demonstration batchFirst patient enrolled in pivotal CHABLIS 7.5 clinical study of blisibimodPositive trends from analysis of BRIGHT-SC Phase 2 clinical study
HAYWARD, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH) today provided a business update and reported financial results for the second quarter ended June 30, 2016.
Recent Developments and Business Highlights:
Sollpura (liprotamase) Exocrine Pancreatic Insufficiency... More
